| HS Code | 870815 |
| Iupac Name | (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one |
| Molecular Formula | C20H20FNO4 |
| Molecular Weight | 357.38 g/mol |
| Appearance | White to off-white solid |
| Cas Number | 161177-96-0 |
| Melting Point | 142-146°C |
| Solubility | Soluble in DMSO and DMF; sparingly soluble in water |
| Optical Rotation | [α]D20 = +37.0° (c=1.0, CHCl3) |
| Purity | ≥98% (HPLC) |
| Storage Temperature | 2-8°C |
As an accredited (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | A sealed amber glass vial containing 1 gram of (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one, labeled with chemical name and hazard warnings. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL): Securely loads bulk (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one for efficient, safe international shipping. |
| Shipping | The chemical `(S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one` will be shipped in a tightly sealed, inert container within a secondary protective package. Standard protocols are followed for temperature-sensitive and hazardous materials, ensuring compliance with all relevant regulations for safe and secure transport. Shipping documentation and SDS are included. |
| Storage | Store (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one in a tightly sealed container, protected from light and moisture. Keep at 2–8 °C in a refrigerator unless otherwise specified by the supplier. Ensure the storage area is well-ventilated, away from incompatible substances, and clearly labeled. Avoid exposure to heat, direct sunlight, and sources of ignition. |
| Shelf Life | The shelf life of (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one is typically 2 years under cool, dry conditions. |
As a specialized producer of advanced chemical intermediates, we supply (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one for use in high-value industrial segments where strict process control and reproducible chiral induction are required. Below we detail key downstream pathways that rely on this material for targeted synthesis and formulation activities.
Our oxazolidinone derivative functions as a chiral auxiliary in the production of complex pharmaceutical intermediates, including anti-infective agents and CNS therapeutics. Process chemists use it to induce high enantiomeric excess during enolate alkylation and aldol reactions, which significantly impacts API purity and downstream yield. Formulation strategies depend on careful adjustment of reaction temperature, solvent systems, and auxiliary-to-substrate ratios to meet regulatory purity demands.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Downstream agrochemical manufacturers employ this material as a key intermediate for constructing fluorinated aromatic compounds with herbicidal and insecticidal activity. The oxazolidinone unit introduces stability in the synthesis of active ingredients with improved field persistence and reduced off-target toxicity. Application specialists emphasize process qualification, residue management, and compliance with regional MRL standards.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Process R&D departments in antiviral manufacturing implement this compound to enable the selective formation of chiral centers in nucleoside analogs, essential for next-generation antiviral candidates. Its use is critical during nucleophilic addition and aldol phases, where precise stereochemistry dictates biological activity and regulatory approval prospects. Quality units maintain dedicated trace impurity monitoring and handle auxiliary removal to GMP specifications.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers in the fine chemical sector integrate this oxazolidinone structure in the multi-step preparation of advanced chiral ligands. These ligands service high-throughput catalysts for asymmetric hydrogenations and other metal-catalyzed transformations. Downstream users in specialty chemical manufacturing adapt ligand precursor form and purity according to specific catalysis needs while monitoring batch homogeneity and chiral selectivity.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers of advanced materials utilize this intermediate for constructing specialty monomers and oligomers with defined chiral properties for polymer science and surface modification. Its integration provides a platform for achieving unique material functions—such as improved enantioselective binding or tailored wettability—that conventional achiral monomers cannot match. Production-scale synthesis adheres to customer-specific quality and purity requirements, reinforced by feedback loop with development labs.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Every time the name (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one turns up in a research proposal or a batch request, it brings to mind the intricate craft behind the molecules we build every day in our plant. Synthetic chemists spent years tuning each step of the route to this particular oxazolidinone, and the result shows up not just in yield or purity graphs, but in the eyes of a QC team that spots a consistent, clean NMR spectrum. It’s easy to view a molecule as just a structure; inside a chemical manufacturing floor, it becomes the product of scrutiny, repetition, and adjustments rarely seen outside our field.
Years ago, in the days when racemates dominated many process lines, the challenge of separating or controlling stereochemistry often cost more time and money than anyone liked to admit. Getting a reliable, enantiomerically enriched oxazolidinone changed not just a step in the organic synthesis; it cut down whole categories of side-products and simplified downstream reactions. (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one stands out in that regard. Our process applies a chiral auxiliary strategy developed through long cycles in kilo labs, not borrowed from the literature for convenience. This isn't just for the sake of the molecule itself; it's what makes complex syntheses streamlined, cost-effective, and reproducible in any medicinal or process chemistry program that uses it.
From the moment we scaled (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one from hundreds of grams to multi-kilo batches, the trickiest part was nailing both purity and stereochemical integrity together on a larger scale. Other manufacturers sometimes talk only about HPLC traces and optical rotation. What our technical team learned, through more than a hundred runs, is that subtle changes in temperature, agitation, or even the lot of a Grignard reagent can make the difference between an excellent product and a batch that sits uncomfortably outside the specification window.
Over the years, some have suggested shortcuts, hoping to edge out a better throughput or cut down reaction times. Consistent feedback from research collaborators reminds us that the optimal product is not just about numbers. A researcher downstream asks for repeatability, day after day, so confident formulation steps depend on structural and chiral purity, not luck. That trust comes only after exhaustive root-cause analysis, analytical development, and batch documentation that shows every variable tracked down, every deviation closed out.
The reason chemists seek out this specific oxazolidinone isn’t hard to trace. For those working in medicinal chemistry programs—especially on the design of new chiral active pharmaceutical ingredients—this compound enables focused synthesis routes toward fluorinated and phenyl-substituted molecules. Our real customer base isn’t buying a curiosity or a filler; they seek out the performance edge this intermediate brings in asymmetric transformations like aldol additions or Michael reactions.
Supporting these programs from the point of kilogram-scale delivery provides a vantage point into how synthesis groups actually solve problems on the bench. Clients with reliability issues from alternate sources used to face setbacks with smeared chromatograms or ambiguous ee results. Engaging with their teams during process validation runs, we saw that reliable oxazolidinones sharply reduce ambiguity, drive higher throughput in subsequent coupling or reduction steps, and minimize the need for post-reaction resolution and column purification.
While printed specifications on a paper sheet offer a snapshot, real manufacturer confidence comes from knowing the process delivers those specs every time. Our tracked batches of (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one consistently achieve chemical purity of at least 99%, while chiral purity measurement by HPLC sits comfortably above 98% enantiomeric excess. Moisture and residual solvents, sometimes overlooked by those outside pharma, receive full attention in each lot, measured by GC and KF titration.
End users in route scouting call out these details. They don’t just care about the gross structure. Respect for downstream catalysis steps means every potential impurity—aromatic byproducts, residual reagents, hydrate forms—has to see scrutiny during release testing. Our QC facility makes no assumptions; spectra are matched lot by lot against internal standards, with raw data archived for independent verification should the need ever arise.
Chemists considering alternatives sometimes ask how this material stacks up against racemic analogs or other chiral oxazolidinones. The core difference starts at the synthesis—ours avoids epimerization, ruled out with rigorous chiral analysis on every batch. Cheaper, racemic materials might suit quick screens, but in real medicinal chemistry programs their extra separation work and unpredictable side reactions cost weeks of labor and grams of starting materials.
Some substitute molecules with altered aryl or alkyl groups diverge in their physical and chemical behavior. Anyone who’s run columns on substituted oxazolidinones knows how fast retention times and solvent profiles jump around. The 4-fluorophenyl group confers a tangible difference in pi-stacking interactions, with the downstream product often showing tighter spots on silica and increased resistance to hydrolysis, cutting down on fiddly reaction workups and permitting higher overall yields. It might not be a selling point highlighted in a brochure, but clear-headed chemists see the downstream benefits in time saved, not just milligrams gained.
In-house, we keep (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one under controlled ambient conditions—cool, dry, and sealed from atmospheric moisture. Our long-term stability studies indicate it handles the rigors of regular international air and surface transport without significant loss in purity or chiral composition, even when transit times vary. This doesn’t come down to a single packaging choice, but continual monitoring of packaging performance in different climates.
Clients in humid or tropical regions sometimes ask about degradation, especially during the wet season. We’ve seen only negligible shifts in material properties over typical lead times, provided the containers arrive intact, and that comes from years of tracking shipments globally. The real variable lies not in the compound, but in customs holdups or unplanned warehouse stops. Quick monitoring at receiving—basic melting point and handedness checks—serves teams well and nudges everyone along before full scale runs ramp up.
Synthetic groups working with our batches have tipped us off to the value of predictable preparation. Whether the route runs through aldol, allylation, or variant addition chemistry, chemists gain time and confidence from reproducible conversion rates. We supply technical support throughout, up to and including custom-scale pilot lots, only after repeated pilot demonstrations.
Some of our earliest clients shared that their former suppliers sent mixed lots or changed synthetic routes without adequate flagging, impacting crystallizations and downstream purification. In response, our team layered in QA traceability, batch audit trails, and multi-point control of critical intermediates. Over time, those careful practices reduced return requests and repeat phone calls, saving both us and our clients from unnecessary delays and loss.
Users working with similar oxazolidinone intermediates sometimes switch between our product and competitor materials in parallel routes. They often return to ours because fewer side products show up by TLC, and the crystalline solid remains stable on shelf over the full expected run cycle. Feedback cycles into the plant floor, leading technicians to tune filtration and drying steps, always chasing smaller particle sizes or improved powder flow for easier weighing and handling in process lines.
Some assume working at scale just ups the batch volume, but the reality in chemical manufacturing brings extra challenge with scale: heat gradients, mixing profiles, even the physical shape of reaction vessels play a part in batch consistency. To prove our plant process for (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one, we ran small pilot lots repeatedly, then slowly scaled up with incremental quality controls at every stage. Outliers pinpoint issues missed at low scale—something only full manufacturers get to see up close.
Clients sometimes pressure us for rapid scale-ups to meet tight project deadlines. Experience has taught that cutting corners, skipping intermediate purifications, or compressing solvent removal times rarely pays off in yield or quality. Instead, our teams invest time in staged scale-up protocols and cross-team reviews, integrating feedback from both process engineers and analytical chemists. Those real-world adjustments, not just written SOPs, preserve chiral purity and limit costly batch reworks.
Higher standards in molecule design call for reliable sources of chiral starting materials. Pharmaceutical advances today often depend on fine-tuned intermediates, since the wrong stereochemistry delays not only process validation, but also regulatory milestones. What (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one brings is more than just another link in the synthetic chain. It's an assurance—built in glassware, reaction columns, and years’ worth of logged results—that chemists from Boston to Beijing can take on the next challenge with confidence in their starting material.
We work with clients who push boundaries in drug candidate design and route engineering, not just those following well-trodden literature procedures. Some blend requirements for scale with rapid iteration, and others ask for creative changes—modest functional swaps or adjustments to purity thresholds. We've grown accustomed to collaborating closely, tracking not just immediate QC pass rates, but the compound's outright utility in inventive new syntheses. Internal teams keep watch for trends in modification requests, so we can pivot development cycles and accommodate the new needs as they arise in real time.
The chemical field, more than many, hinges on trust in supply chains—and trust is earned when manufacturers speak plainly and show transparency from process to paperwork. Clients who visit our site witness the steps themselves: glass-lined reactors in action, analytical teams unpacking each chromatogram, senior staff revisiting deviation records together. Over time, the collaborative energy between clients and in-house experts creates an environment where improvements come not because of compliance checklists, but from a real desire to see science progress without unnecessary setbacks.
Direct engagement between bench chemists and our technical support has led to new batch protocols, investing in more robust filtration gear, even changes in packaging material to prevent static or clumping. Feedback didn’t just go into a report; it led to visible change in how every kilo hits the loading dock. We believe in documenting and sharing lessons learned, not as marketing talk, but because it drives close relationships and outcomes that benefit both sides.
Manufacturing this level of enantiopure, functionally complex oxazolidinone demands real investment: in raw materials, in staff training, in robust analytic methodology. Early on, we faced competing offers from lower-cost, lower-purity competitors, some pushing less rigorous QA protocols. Consistent feedback from experienced buyers confirms the real price is measured not at purchase, but in lost time and failed experiment cycles down the line. Our resolve to keep standards high reflects not just internal pride, but respect for those who use our material as the stage for new innovations.
Years of routine batch production did not flatten our appetite for learning. Teams rotate through pilot lines and scale-up projects, always aiming to spot potential weaknesses before they show up in a customer’s lab. Process safety and environmental concerns, often sidelined by those focused only on specification sheets, are under continual review. We run frequent audits of waste treatment protocols and push for more sustainable alternatives; minimizing waste streams always brings knock-on benefits to both environment and cost.
Our core belief is that grounded, actual experience creates the most reliable, most useful intermediates for the next wave of chemical discovery. (S)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one stands as an example, not of generic supply, but of ongoing engagement, technical feedback, and the drive to see synthetic chemistry succeed at every scale and every bench—without surprise setbacks, ambiguous results, or missed deadlines. Each batch tells the story, and every story starts in the hands of experienced chemists, on both sides of every transaction.